Publication Date:
2011-03-25
Description:
A sensitive and specific liquid chromatography–electrospray ionization–tandem mass spectrometry method has been developed and validated for the identification and quantification of brivudine in human plasma using diclofenac as an internal standard. The method involves extraction with ethyl acetate. The analyte was separated on a C 18 column and analyzed in multiple reaction monitoring mode with a negative electrospray ionization interface using the [M–H] − ions, m / z 332.8→ m / z 80.9 for brivudine, m / z 293.6→ m / z 249.5 for diclofenac. The method was validated over the concentration range of 5.54–2,836 μg L −1 for brivudine. The intra-and inter-day precisions were less than 8.91% in terms of relative standard deviation (RSD), and the accuracy was within −4.22% in terms of relative error (RE). The lower limit of quantification (LLOQ) was 5.54 μg L −1 with acceptable precision and accuracy. There were almost no matrix effects. Recovery of brivudine spiked in drug-free plasma was higher than 77.17%. The method was used to study the pharmacokinetic profile of brivudine in human plasma after oral administration of brivudine tablets. Content Type Journal Article Pages 1-7 DOI 10.1007/s10337-011-2001-y Authors Xiang-Dong Peng, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, 410078 Hunan People’s Republic of China Zhi-Rong Tan, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, 410078 Hunan People’s Republic of China Hui-Zi Wu, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, 410078 Hunan People’s Republic of China Gan Zhou, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, 410078 Hunan People’s Republic of China Chen-Xian Guo, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, 410078 Hunan People’s Republic of China Qi Pei, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, 410078 Hunan People’s Republic of China Shan Cao, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, 410078 Hunan People’s Republic of China Xiang-Guang Meng, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, 410078 Hunan People’s Republic of China Yi-Cheng Wang, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, 410078 Hunan People’s Republic of China Yao Chen, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, 410078 Hunan People’s Republic of China Dong Guo, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, 410078 Hunan People’s Republic of China Lan Fan, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, 410078 Hunan People’s Republic of China Wei Zhang, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, 410078 Hunan People’s Republic of China Hong-Hao Zhou, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, 410078 Hunan People’s Republic of China Journal Chromatographia Online ISSN 1612-1112 Print ISSN 0009-5893
Print ISSN:
0009-5893
Electronic ISSN:
1612-1112
Topics:
Chemistry and Pharmacology
Permalink